Rossari Biotech Limited informed the Exchange regarding Press Release dated July 18, 2026 titled " Rossari Biotech Limited announces Q1 FY 27 results".
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 19 Jul 2026, 04:28 PM IST · BSE ID: 073c237d-457f-4e5d-b352-2166c1c213f8
View Original BSE Filing (PDF)
💡
In Simple Terms
Rossari Biotech saw its sales rise by 28% to Rs. 697.2 crore in Q1 FY27, with profit up 4%.
🤖 AI Summary
- Rossari Biotech reported highest-ever quarterly Revenue of Rs. 697.2 crore for Q1 FY27, up 28% YoY.
- EBITDA for Q1 FY27 reached Rs. 80.6 crore, representing a 19% increase YoY.
- Profit After Tax (PAT) for Q1 FY27 was Rs. 35.1 crore, an increase of 4% YoY.
- New greenfield blending facility established in Thailand with 5,000 MTPA capacity to serve Southeast Asia.
- Completed sale of the Andheri office, marking further progress in monetisation of non-core assets.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from operations Q1 FY27
Rs. 697.2 crore
28%
Consolidated Revenue from operations Q1 FY26
Rs. 543.7 crore
Consolidated EBITDA Q1 FY27
Rs. 80.6 crore
19%
Consolidated EBITDA Q1 FY26
Rs. 67.9 crore
Consolidated PAT Q1 FY27
Rs. 35.1 crore
4%
Consolidated PAT Q1 FY26
Rs. 33.6 crore
Consolidated EBITDA margin Q1 FY27
11.6%
Consolidated EBITDA margin Q1 FY26
12.5%
Consolidated EPS (Diluted) Q1 FY27
Rs. 6.3
Consolidated EPS (Diluted) Q1 FY26
Rs. 6.1
Standalone Revenue from operations Q1 FY27
Rs. 482.3 crore
32%
Standalone PAT Q1 FY27
Rs. 34.3 crore
31%
🏢 How This Affects the Company
The company recorded its highest-ever quarterly revenue, driven by domestic business momentum and international expansion into Southeast Asia with a new Thailand facility. This supports broader market penetration and expanded application of specialty solutions.
Consolidated revenue increased by 28% to Rs. 697.2 crore, and PAT increased by 4% to Rs. 35.1 crore. EBITDA margin decreased to 11.6% from 12.5% YoY, impacting profitability growth relative to revenue.
The establishment of a greenfield blending facility in Thailand enhances capabilities for customised formulations and improves supply chain efficiency in Southeast Asia. The sale of non-core assets like the Andheri office streamlines the asset base.
👥 What This Means For Shareholders
✅
Action Required
No immediate action required by shareholders based on this results announcement.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the 28% YoY consolidated revenue growth and 4% YoY PAT growth in Q1 FY27.
🔍
Management Signal
Management focuses on disciplined execution, innovation, and profitable growth, supported by strategic investments in manufacturing and international presence.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — monitor consolidated revenue and PAT growth rates.
Update on Thailand facility utilisation and revenue contribution.
Progress on further monetisation of non-core assets.
LOW RISK
The filing indicates positive operational and financial performance with strategic expansion.
💡 Investor Takeaway
Rossari Biotech reported Q1 FY27 consolidated revenue of Rs. 697.2 crore, up 28% YoY from Rs. 543.7 crore. Consolidated PAT was Rs. 35.1 crore, a 4% YoY increase from Rs. 33.6 crore. EBITDA margin contracted from 12.5% to 11.6%.
⚖️ Strengths & Concerns
✅ Positives
- Achieved highest-ever quarterly consolidated revenue of Rs. 697.2 crore in Q1 FY27, demonstrating strong top-line growth.
- Established a new 5,000 MTPA greenfield blending facility in Thailand, strengthening international presence and local market responsiveness.
⚠️ Concerns
- Consolidated EBITDA margin decreased to 11.6% in Q1 FY27 from 12.5% in Q1 FY26, indicating cost pressures relative to revenue growth.
- Consolidated PAT growth of 4% YoY (Rs. 35.1 crore) significantly lagged revenue growth of 28% YoY, impacting bottom-line expansion.
📅 Company Track Record
Rossari Biotech's previous filing on July 19, 2026, also reported Q1 FY27 consolidated revenue grew 28.2% YoY to Rs. 697.2 crore, consistent with this press release. The Board had also approved 4000 ESOP options and an internal subsidiary transfer on July 18, 2026.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Rossari Biotech's consolidated revenue for Q1 FY27?
Rossari Biotech's consolidated revenue from operations for Q1 FY27 was Rs. 697.2 crore, representing a 28% increase compared to Q1 FY26.
What was Rossari Biotech's Profit After Tax (PAT) for Q1 FY27?
The consolidated Profit After Tax (PAT) for Rossari Biotech in Q1 FY27 was Rs. 35.1 crore, which is a 4% increase from Rs. 33.6 crore in Q1 FY26.
How did Rossari Biotech's EBITDA perform in Q1 FY27?
Consolidated EBITDA for Rossari Biotech improved by 19% to Rs. 80.6 crore in Q1 FY27 from Rs. 67.9 crore in Q1 FY26. However, the EBITDA margin was 11.6% compared to 12.5% in the prior year.
What new operational development did Rossari Biotech announce?
Rossari Biotech established a greenfield blending facility in Thailand through its subsidiary, Unistar Thai, with an installed capacity of 5,000 MTPA to serve Southeast Asia.
Questions based on this BSE filing only. For information purposes.